Pharmaids Pharmaceuticals Ltd

Pharmaids Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 28 May 2025. However, the analysis and financial metrics presented here reflect the stock’s current position as of 27 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Pharmaids Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 28 May 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 16 June 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Pharmaids Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 28 May 2025. However, the analysis and financial metrics presented here reflect the company’s current position as of 03 June 2026, providing investors with the latest insights into its performance and outlook.

A sharp decline of 15.62% in intraday trading dragged Pharmaids Pharmaceuticals Ltd to a fresh 52-week low of Rs 25.6 on 1 Jun 2026, extending its downward trajectory amid persistent selling pressure.

Pharmaids Pharmaceuticals Ltd., a Hyderabad-based contract research and manufacturing services company, reported its Q4 FY26 results that reveal a troubling paradox: robust revenue growth coupled with deteriorating profitability. The micro-cap pharmaceutical firm posted a consolidated net loss of ₹1.81 crores for the March 2026 quarter, marking a 27.02% sequential decline and a 54.06% year-on-year deterioration, even as net sales surged 50.52% YoY to ₹7.18 crores.

Pharmaids Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 28 May 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 22 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Pharmaids Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 28 May 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 11 May 2026, providing investors with an up-to-date perspective on the stock’s fundamentals, valuation, financial trends, and technical outlook.

Pharmaids Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 28 May 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 29 April 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trends, and technical outlook.

Pharmaids Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 28 May 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 18 April 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical outlook.

Pharmaids Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 28 May 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 07 April 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

A sharp decline has pushed Pharmaids Pharmaceuticals Ltd to a fresh 52-week low of Rs 28.5 on 30 Mar 2026, marking a significant 61.2% drop from its peak of Rs 73.45 within the last year. This steep fall comes amid a broader market downturn, but the stock’s underperformance far exceeds sector and benchmark indices.

Pharmaids Pharmaceuticals Ltd’s stock price declined sharply on 27 Mar 2026, hitting a new 52-week low of Rs.29.05. This marks a significant downturn for the micro-cap pharmaceutical company, reflecting ongoing pressures in its financial performance and market positioning.

Pharmaids Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 28 May 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Pharmaids Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 28 May 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 13 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Pharmaids Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 28 May 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 02 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Pharmaids Pharmaceuticals Ltd’s shares declined sharply to a new 52-week low of Rs.30 today, marking a significant drop amid a challenging market environment. The stock underperformed its sector and broader indices, reflecting ongoing concerns about the company’s financial health and market position.

Pharmaids Pharmaceuticals Ltd has reached a new 52-week low of Rs.30.56, marking a significant decline in its stock price amid broader market gains. The stock underperformed its sector and continues to trade below all key moving averages, reflecting ongoing pressures within the company’s financial and operational metrics.